Quetiapine Dosing for Bipolar Depression
For bipolar depression, start quetiapine at 50 mg once daily at bedtime on Day 1, then titrate to the target dose of 300 mg/day by Day 4, administered as a single bedtime dose. 1
Specific Titration Schedule
The FDA-approved dosing regimen for bipolar depression follows this precise escalation 1:
- Day 1: 50 mg at bedtime
- Day 2: 100 mg at bedtime
- Day 3: 200 mg at bedtime
- Day 4: 300 mg at bedtime (target dose)
The maximum dose is 300 mg/day for bipolar depression - notably lower than the 400-800 mg/day used for acute mania. 1
Key Dosing Distinctions
This is a critical point: bipolar depression requires substantially lower doses than bipolar mania. While acute mania is treated with 400-800 mg/day divided into multiple doses 1, bipolar depression responds to 300 mg/day given once daily at bedtime. This once-daily bedtime dosing is both more convenient and leverages the sedating properties to improve sleep, which is often disrupted in bipolar depression.
Evidence Supporting 300 mg Dose
Multiple high-quality trials (BOLDER I and II) demonstrated that both 300 mg and 600 mg doses were significantly superior to placebo for bipolar depression, with no additional benefit from the higher 600 mg dose 2, 3. The 300 mg dose showed:
- Response rates of 57.6% vs 36.1% for placebo
- Remission rates of 52.9% vs 28.4% for placebo
- Significant improvement from Week 1 onward 3
The extended-release formulation at 300 mg once daily also demonstrated efficacy comparable to immediate-release 4.
Special Population Adjustments
Elderly or debilitated patients: Start at 50 mg/day and increase in 50 mg increments based on response and tolerability 1
Hepatic impairment: Start at 25 mg/day and increase in 25-50 mg increments to effective dose 1
Drug interactions:
- With strong CYP3A4 inhibitors (ketoconazole, ritonavir): Reduce dose to one-sixth of original
- With strong CYP3A4 inducers (phenytoin, carbamazepine): May need up to 5-fold dose increase 1
Critical Safety Considerations
Common adverse effects at 300 mg include dry mouth (44%), somnolence (57%), dizziness (18%), and constipation (10%) 1. These are generally dose-related and more tolerable at the 300 mg dose compared to higher doses used for mania.
Low risk of treatment-emergent mania: Rates were similar to placebo (3.2% vs 3.9%) in controlled trials 3, though there are case reports suggesting very low doses (<300 mg) may paradoxically worsen mania through differential receptor antagonism 5. This underscores the importance of reaching the therapeutic 300 mg dose rather than remaining at subtherapeutic doses.
Metabolic monitoring is essential: weight gain occurred in 4% of patients, and lipid/glucose parameters should be monitored regularly 1.
Maintenance Treatment
For patients who respond to acute treatment, continuation at the same dose (300 mg/day) significantly reduces risk of mood episode recurrence (HR 0.51, p<0.001), particularly depressive episodes (HR 0.43, p<0.001) 6. The efficacy is maintained for 26-52 weeks of continued treatment.